Sign in →

Test Code GANC Ganciclovir, Serum

Reporting Name

Ganciclovir, S

Useful For

Monitoring patients on ganciclovir

Method Name

High-Performance Liquid Chromatography (HPLC)

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum Red

Specimen Required

Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: 

1. Serum for a peak level should be drawn 30 to 60 minutes after dosing. Serum for a trough level should be drawn no more than 30 minutes before the next dose.

2. Spin down within 2 hours of draw.

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen (preferred) 28 days
  Refrigerated  14 days
  Ambient  7 days

Reject Due To


Mild reject; Gross reject


Mild OK; Gross OK


Mild OK; Gross OK


Serum gel tube

Reference Values

Trough: 1.0-3.0 mcg/mL

Peak: 3.0-12.5 mcg/mL

Day(s) and Time(s) Performed

Thursday; 11 a.m.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
GANC Ganciclovir, S 15367-6


Result ID Test Result Name Result LOINC Value
80140 Ganciclovir, S 15367-6

Analytic Time

2 days


Usage should be discontinued if absolute neutropenia develops.

Method Description

High-Performance Liquid Chromatography (HPLC).(Unpublished Mayo method)


Serum concentrations of ganciclovir do not correlate well to toxicity or efficacy. Peak and trough levels provided are representative of typical serum concentrations seen during therapy, but individual values must be interpreted in conjunction with the clinical status of the individual patient and the specific characteristics of the infecting microorganism.

Specimen Retention Time

14 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Clinical Information

Ganciclovir, an analog of acyclovir, demonstrates inhibitory action against some viruses including herpes virus, cytomegalovirus, and HIV. Therapeutic ranges have not been well-established for ganciclovir; current ranges are based on typical values seen during ganciclovir therapy and do not correlate well to toxicity or outcome. Monitoring of ganciclovir serum concentrations may be most useful in guiding therapy in patients with renal dysfunction. Myelosuppression is the major dose-limiting side effect of ganciclovir.


Valcyte (valganciclovir) is an oral prodrug of ganciclovir ester. It is immediately converted to ganciclovir once it enters the bloodstream. The oral dose is designed to deliver ganciclovir equivalent to intravenous ganciclovir at 5 mg/kg.